Journal
SCIENCE
Volume 338, Issue 6109, Pages 903-910Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1226338
Keywords
-
Categories
Funding
- NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) [R01-EB012065]
- National Cancer Institute [R01-CA157766]
- NIBIB [R21-EB013226, R21-EB013754]
- National Heart, Lung, and Blood Institute [RO1 HL087036]
Ask authors/readers for more resources
Nanoparticle-based drug delivery systems have been developed to improve the efficacy and reduce the systemic toxicity of a wide range of drugs. Although clinically approved nanoparticles have consistently shown value in reducing drug toxicity, their use has not always translated into improved clinical outcomes. This has led to the development of multifunctional nanoparticles, where additional capabilities like targeting and image contrast enhancement are added to the nanoparticles. However, additional functionality means additional synthetic steps and costs, more convoluted behavior and effects in vivo, and also greater regulatory hurdles. The trade-off between additional functionality and complexity is the subject of ongoing debate and the focus of this Review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available